The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.
 
Wei Li
No Relationships to Disclose
 
Anwen Xiong
No Relationships to Disclose
 
Nong Yang
No Relationships to Disclose
 
Huijie Fan
No Relationships to Disclose
 
Qitao Yu
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Xue Meng
No Relationships to Disclose
 
Jingxun Wu
No Relationships to Disclose
 
Ziping Wang
No Relationships to Disclose
 
Yunpeng Liu
No Relationships to Disclose
 
Xicheng Wang
No Relationships to Disclose
 
Xintian Qin
No Relationships to Disclose
 
Kaihua Lu
No Relationships to Disclose
 
Wu Zhuang
No Relationships to Disclose
 
Yizhong Ren
Employment - Anheart Therapeutics
 
Xianyu Zhang
Employment - Anheart Therapeutics
 
Bing Yan
Employment - Anheart Therapeutics
 
Christine M. Lovly
Honoraria - Amgen; Anheart Therapeutics; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Cepheid; D2G Oncology; Daiichi Sankyo/Astra Zeneca; EMD Serono; Foundation Medicine; Genentech; Gilead Sciences; InduPro; Janssen Oncology; Lilly; Pfizer; Syros Pharmaceuticals; Syros Pharmaceuticals; Takeda
Research Funding - AstraZeneca (Inst); Novartis; Xcovery
(OPTIONAL) Uncompensated Relationships - Johnson & Johnson/Janssen; Roche/Genentech
 
Caicun Zhou
Honoraria - Amoy Diagnostics; Anheart Therapeutics; Boehringer Ingelheim; C-Stone LUYE Pharma; Hengrui Pharmaceutical; Innovent Biologics; Lilly; MSD; QiLu Pharmaceutical; Roche; Sanofi; TopAlliance BioSciences Inc
Consulting or Advisory Role - Hengrui Pharmaceutical; Innovent Biologics; QiLu Pharmaceutical; TopAlliance BioSciences Inc
Speakers' Bureau - Amoy Diagnostics; Anheart Therapeutics; Boehringer Ingelheim; C-Stone LUYE Pharma; Hengrui Pharmaceutical; Innovent Biologics; Lilly; MSD; QiLu Pharmaceutical; Roche; Sanofi; TopAlliance BioSciences Inc